- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Looking Back at CAR T: PROs From a Patient's Perspective
A survivor of chronic lymphocytic leukemia who participated in the first chimeric antigen receptor T-cell trial in 2010 looks back at his experience and also discusses his views on how patient-reported outcomes (PROs) should be used, if at all, by CMS.
There are 2 approved chimeric antigen receptor (CAR) T-cell therapies on the market for patients with advanced leukemias and lymphomas, Novartis’ tisagenlecleucel (Kymriah) and Kite Pharma/Gilead’s axicabtagene ciloleucel (Yescarta). These immunotherapies are revolutionizing cancer treatment, albeit at great cost.
Doug Olson, a survivor of chronic lymphocytic leukemia, participated in the first CAR T trial in 2010, and joined a recent meeting of the Medicare Evidence Development and Coverage Advisory Committee convened by CMS to discuss how patient-reported outcomes (PROs) should be used, if at all, in any future coverage decisions.
He discussed his experience with CAR T, and his thoughts about PROs and costs, in a podcast after the meeting.
You may need to login to listen to the podcast.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or through one of these podcast services:
MEDCAC Panel Mostly Endorses PROs for CAR T Therapies
Many Questions to Ask in Setting National Coverage for CAR T Therapies
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
Learn more about CAR T:
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
